RAMM Pharma Beheer

Beheer criteriumcontroles 2/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Jack Burnett

Algemeen directeur

CA$426.6k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	5.1yrs
Eigendom CEO	17.9%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

How Much Are RAMM Pharma Corp. (CSE:RAMM) Insiders Taking Off The Table?

Dec 18

Analyse CEO-vergoeding

Hoe is Jack Burnett's beloning veranderd ten opzichte van RAMM Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2024	n/a	n/a	-CA$9m
Apr 30 2024	n/a	n/a	-CA$9m
Jan 31 2024	n/a	n/a	-CA$8m
Oct 31 2023	CA$427k	CA$427k	-CA$8m
Jul 31 2023	n/a	n/a	-CA$20m
Apr 30 2023	n/a	n/a	-CA$20m
Jan 31 2023	n/a	n/a	-CA$21m
Oct 31 2022	CA$675k	CA$418k	-CA$21m
Jul 31 2022	n/a	n/a	-CA$7m
Apr 30 2022	n/a	n/a	-CA$9m
Jan 31 2022	n/a	n/a	-CA$8m
Oct 31 2021	CA$467k	CA$467k	-CA$7m
Jul 31 2021	n/a	n/a	-CA$7m
Apr 30 2021	n/a	n/a	-CA$6m
Jan 31 2021	n/a	n/a	-CA$7m
Oct 31 2020	CA$390k	CA$390k	-CA$7m

Compensatie versus markt: Jack's total compensation ($USD305.64K) is above average for companies of similar size in the Canadian market ($USD171.96K).

Compensatie versus inkomsten: Jack's compensation has been consistent with company performance over the past year.

CEO

Jack Burnett

5.1yrs

Tenure

CA$426,569

Compensatie

Mr. Jackie Peter Burnett also known as Jack, serves as President, Chief Executive Officer and Chairman at Ramm Pharma Holdings Corp. (Formerly known as Ramm Pharma Corp.) and serves as its Director since O...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jackie Burnett	President	5.1yrs	CA$426.57k	17.88% CA$ 213.5k
Daniel Augereau	Independent Director	5.1yrs	CA$20.00k	9.05% CA$ 108.0k
Eric Klein	Independent Director	5.1yrs	CA$20.00k	geen gegevens

5.1yrs

Gemiddelde duur

Ervaren bestuur: RAMM's board of directors are considered experienced (5.1 years average tenure).

RAMM Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

RAMM Pharma Corp. Announces Chief Financial Officer Changes

Recent updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in 2Q 2023)

RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024

New major risk - Financial position

Full year 2023 earnings released: CA$0.064 loss per share (vs CA$0.17 loss in FY 2022)

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.009 loss in 3Q 2022)

RAMM Pharma Corp. Common Shares to Be Deleted from OTC Equity

Insufficient new directors

Insufficient new directors

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.012 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.016 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.17 loss per share (vs CA$0.066 loss in FY 2021)

Insufficient new directors

RAMM Pharma Corp. Announces Chief Financial Officer Changes

Insufficient new directors

Third quarter 2022 earnings released: CA$0.009 loss per share (vs CA$0.03 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

RAMM Pharma Corp., Annual General Meeting, Apr 07, 2022

High number of new and inexperienced directors

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.018 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.012 loss in 2Q 2020)

RAMM Pharma Corp. (CNSX:RAMM) agreed to acquire the remaining 51% stake in Canapar S.r.L. for approximately $26.2 million.

Jack Burnett, President and a director of Ramm Pharma, Daniel Augereau, a director of Ramm Pharma and an unknown buyer acquired approximately 10% stake in RAMM Pharma Corp. (CNSX:RAMM) from Armando Blankleider for CAD 2.3 million.

First quarter 2021 earnings released: CA$0.015 loss per share (vs CA$0.02 loss in 1Q 2020)

New 90-day high: CA$1.14

Full year 2020 earnings released: CA$0.074 loss per share (vs CA$0.14 loss in FY 2019)

RAMM Pharma Selects as COVID-19 Vaccine Fulfilment & Distribution Partner by the Uruguayan Ministry of Health

New 90-day high: CA$1.05

Canapar Corp. and RAMM Pharma Corp. enters into Strategic Partnership

New 90-day high: CA$0.75

New 90-day high: CA$0.68

Canopy Rivers Inc. (TSX:RIV) acquired an additional 49% stake in Canapar S.r.L. from RAMM Pharma Corp. (CNSX:RAMM) for $9 million.

How Much Are RAMM Pharma Corp. (CSE:RAMM) Insiders Taking Off The Table?

New 90-day low: CA$0.45

Ramm Pharma Corp. Commences Sales of Epifractán Products Through Peruvian Pharmacies

Third quarter earnings released

New 90-day high - CA$0.60

New 90-day high - CA$0.54

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur